FindTrial
Sign In

Re-evaluation of the therapeutic efficacy of different intermittent transcutaneous electrical stimulation modalities for the genioglossus muscle in the treatment of obstructive sleep apnea

Re-evaluation of the therapeutic efficacy of different intermittent transcutaneous electrical stimulation modalities for the genioglossus muscle in the treatment of obstructive sleep apnea

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114062
Enrollment
Unknown
Registered
2025-12-08
Start date
2025-12-10
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep apnea hypopnea syndrome

Interventions

Intermittent transcutaneous electrical stimulation mode A:Intermittent transcutaneous electrical stimulation mode A
Intermittent transcutaneous electrical stimulation mode B:Intermittent transcutaneous electrical stimulation mode B
Intermittent transcutaneous electrical stimulation mode C:Intermittent transcutaneous electrical stimulation mode C
Intermittent transcutaneous electrical stimulation mode D:Intermittent transcutaneous electrical stimulation mode D

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 65 years old; 2 BMI<30kg/m^2; 3.Diagnosed with obstructive sleep apnea, meeting the standards of the 'Multidisciplinary Diagnosis and Treatment Guidelines for Adult Obstructive Sleep Apnea' formulated by the Sleep Medicine Professional Committee of the Chinese Medical Doctor Association in 2018 4. Sign the informed consent form; 5. No history of pharyngeal surgery except for tonsillectomy, and no palatal tonsillar hypertrophy (grade III or IV); 6. AHI < 30 times/hour; 7. Hospitalized patients

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Diagnosed with OSA and received relevant treatment before enrollment; 3. Hormone related OSA such as hypothyroidism and acromegaly; 4. Patients with heart, brain, liver, kidney, respiratory function impairment or other diseases that affect sleep; 5. Implanted cardiac pacemaker device; 6. Upper airway mass and tumor lesions, significant nasal stenosis or obstruction, significant narrowing or obstruction of the palatopharyngeal plane; 7. Individuals lacking autonomous behavioral abilities.

Design outcomes

Primary

MeasureTime frame
Apnea hyponea index;Oxygen desaturation index;—

Secondary

MeasureTime frame
Adverse reaction;Tolerance;Sleepiness Scale Score;Snoring index;—

Countries

China

Contacts

Public ContactHu Ke

Renmin Hospital of Wuhan University

huke-rmhospital@163.com+86 189 7103 5988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026